Artichoke by-product supplement: testing how the body absorbs polyphenols

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This bioavailability study examines the absorption, distribution, metabolism, and excretion of hydroxycinnamic acids (HCAs) from a dehydrated artichoke by-product supplement. Participants will follow a polyphenol-light diet for 48 hours around a single-dose capsule intake, with blood and urine samples collected over 48 hours to measure the compounds and their metabolites by HPLC-MS. The aim is to identify how much of the active polyphenols become available in the body and how they are handled metabolically. Results could help understand the potential health relevance of these artichoke-derived polyphenols.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men and women between 18 and 75 years of age.
* Normal-weight volunteers (BMI of 18.5-24.9 kg/m²).
* Subjects must be able to understand and willing to sign the informed consent form, and must comply with all study procedures and requirements.

Exclusion Criteria:

* Presence of chronic gastrointestinal pathology.
* Lactating or pregnant women, or those planning to become pregnant.
* Individuals who have taken antibiotics within the 3 months prior to the study.
* Individuals currently taking supplements (plant-derived, fiber, or probiotics) unless they are willing to discontinue use during the 4-day study intervention and ensure a minimum washout period of 14 days prior to baseline measurements.
* Individuals with an alcohol intake \> 80 g/day.
* Presence of allergy or intolerance to artichoke.
* Individuals undergoing treatment with anticoagulants, immunosuppressants, or cytotoxic agents.
* Presence of renal or hepatic failure.
* Presence of immunodeficiency or being HIV positive.
* Subjects with any type of cancer, those undergoing cancer treatment, or those for whom at least 5 years have not passed since remission.
* Presence of weight loss greater than 5% in the 6 months prior to the trial.
* Lack of time or geographical availability to attend the study visits.
* Failure to sign the informed consent form.
* Difficulty in undergoing blood extraction/collection.
* Having donated blood within 14 days prior to the baseline visit.
* Individuals who demonstrate difficulty swallowing capsules, tablets, pills, or similar.

Where it's running

• Universidad de Navarra
  Pamplona, Navarre, Spain Recruiting

Study contacts

• Principal investigator: Iziar A Ludwig Sanz-Orrio — University of Navarra
• Study coordinator: Iziar A Ludwig, PhD
• Email: uinclint@unav.es
• Phone: +34 948425600

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How age affects germinal center responses after flu and rabies vaccines

  Researchers will test how the immune system responds to flu and rabies vaccines in younger adults (18–40) and older adults (65+).

  Recruiting Phase 4 Washington University School of Medicine · St Louis, Missouri · NCT07914673

• Magnetic field maps with NV sensors for non-invasive heart measurements

  This study tests whether diamond-based NV magnetometers can non-invasively detect and map the heart's magnetic field in healthy adults.

  Recruiting Robert Bosch GmbH · Renningen · NCT07908173

• Methylation analyses using home-based self-sampling in women with and without gynecological disease

  This study tests whether self-collected urine and vaginal samples can reveal DNA methylation markers that distinguish people with gynecological (pre-)cancers from cancer-free controls.

  Recruiting Universiteit Antwerpen · Edegem, Antwerp · NCT07902388

• Omega-3 status in healthy adults: comparing different fish-oil and algae-oil products

  This study tests whether various fish-oil and algae-oil products can raise the Omega-3 Index in healthy adults who don’t eat much fatty fish.

  Recruiting Nordic Naturals · London, Ontario · NCT07900425

• A safe, carefully dosed test of TBD11 in healthy adults

  This phase 1 study tests TBD11 in healthy adults to see if it is safe and tolerable and to understand how it behaves in the body, including how it interacts with other medicines.

  Recruiting Phase 1 Gates Medical Research Institute · Bloemfontein · NCT07883226

• Fosmanogepix in healthy adults: how it may interact with other drugs and heart rhythm

  This study tests whether fosmanogepix (and its active form manogepix) changes how other medicines work in healthy adults.

  Recruiting Phase 1 Basilea Pharmaceutica · Groningen, Netherlands · NCT07881224

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.